Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Harbour Bio to Start China Trials of CLTA-4/PD-1 Combo in Two Additional Cancers

publication date: Sep 14, 2021

Harbour BioMed was approved to start China trials of its next-gen CLTA-4 candidate in combination with its PD-1 for two new indications: hepatocellular carcinoma and neuroendocrine tumor/neuroendocrine carcinoma. HBM believes HBM4003, a fully human anti-CTLA-4 mAb, has the potential to improve efficacy while reducing toxicity as a monotherapy and combo-therapy. Earlier this year, the CLTA-4/PD-1 combination started China trials for NSCLC. Harbour is headquartered in Cambridge, MA, with discovery operations in Rotterdam and development labs in Suzhou. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021